Nanoglass textile materials for medical applications
17 Jan '07
2 min read
Pera and biomaterials and stem cell specialist NovaThera have achieved success in the DTI Innovation Competition to lead a consortium that will develop a new NanoGlass nanofibre based textile for medical applications.
The novel textile produced will be made into a woven resorbable scaffold with the capability of delivering drugs, growth factors and cell therapies.
It is envisaged that this will provide a solution to the long-standing problem of failed procedures or infection after skull and face implant surgery. Approximately 200,000 of these procedures are performed across the EEC every year, so a development such as this is long overdue.
”This will reduce implant failure and corrective surgery by up to 50% and will eliminate the need to harvest bone for grafting,” said CEO of NovaThera Gareth Roberts.
Other benefits include the savings that will be realised in medical costs of up to £500 million each year with significant improvements in the cosmetic and clinical outcome of these surgical procedures.
NovaThera Ltd is a regenerative medicine company with interests in both tissue engineering scaffolds and human embryonic stem cells. NovaThera's vision is to be an international leader in identifying and developing the platform technologies and intellectual property which will underpin the development of regenerative therapies.